Use of antisense oligonucleotides in functional genomics and target validation.
With the completion of sequencing of the human genome, a great deal of interest has been shifted toward functional genomics-based research for identification of novel drug targets for treatment of various diseases. The major challenge facing the pharmaceutical industry is to identify disease-causing genes and elucidate additional roles for genes of known functions. Gene functionalization and target validation are probably the most important steps involved in identifying novel potential drug targets. This review focuses on recent advances in antisense technology and its use for rapid identification and validation of new drug targets. The significance and applicability of this technology as a beginning of the drug discovery process are underscored by relevant cell culture-based assays and positive correlation in specific animal disease models. Some of the antisense inhibitors used to validate gene targets are themselves being developed as drugs. The current clinical trials based on such leads that were identified in a very short time further substantiate the importance of antisense technology-based functional genomics as an integral part of target validation and drug target identification.
Ravichandran
Lingamanaidu V
LV
Isis Pharmaceuticals, Carlsbad, CA 92008, USA.
Dean
Nicholas M
NM
Marcusson
Eric G
EG
D023281:Genomics; D016376:Oligonucleotides, Antisense / Q000494:pharmacology*; D014176:Protein Biosynthesis; D034622:RNA Interference; D012326:RNA Splicing; D016914:Ribonuclease H / Q000378:metabolism
D016376:Oligonucleotides, Antisense; D016914:Ribonuclease H